Project Grant R44HL174192
Award Date
9/1/24
Completion Date
6/30/26
Dollars Obligated
$1.3M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Malvern, PA 19355, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $400,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Electronic Biosciences, Inc., a small business biotechnology company. The grant will fund the development of a compact, low-cost analytical device to precisely characterize lipoprotein particles in blood. This advanced technology will provide researchers and clinicians with new capabilities to evaluate cardiovascular disease risk and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,504 to Imetabolic Biopharma Corp to develop a novel therapeutic approach to clear small dense low-density lipoprotein (sdLDL) from circulation. The research aims to create a dual-domain candidate molecule that can specifically target and facilitate the clearance of these highly atherogenic lipoprotein particles. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $407,975 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Arizona State University's Division, doing business as Orspa, to develop a lesion-targeted nanotherapeutic that utilizes CARMN transcripts as a pharmaceutical agent for the treatment of vascular smooth muscle cell (VSMC) dysfunction and neointimal hyperplasia (NIH). The project aims to optimize the CARMN-loaded platelet membrane-cloaked nanoparticles...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,892 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Asclepia Technology LLC, a small business located in Sugar Land, Texas. The goal of this 12-month project is to develop a targeted cellular therapy for treating atherosclerotic vascular disease, a leading cause of death and disability. Specifically, the project will manufacture and test prototypes of dual-functional, echogenic immunoliposomes (DF-ELIP) that...
This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of innovative in vitro assays to evaluate the efficacy and cytotoxicity of new atherosclerosis treatments. The awardee, Endomimetics LLC, is leveraging its proprietary nanomatrix cell sheet technology and "cell-as-glue" approach to create a 3D in vitro vascular sheet model of atherosclerosis. The goal...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,488,899 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Young Therapeutics LLC, a for-profit company based in Philadelphia, Pennsylvania. The grant, effective April 1, 2025 through December 31, 2026, supports the advanced development and validation of two proprietary compounds, YT-002 and YT-004, that target specific protein kinases to preserve myocardial tissue and function following a heart attack.
The key...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $595,464 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cerulean Scientific Inc., a for-profit small business, to develop and optimize a tethered liquid perfluorocarbon (TLP) coating for peripheral vascular grafts. The goal is to improve outcomes for patients with critical limb ischemia by reducing complications such as thrombosis, neointimal hyperplasia, and biofilm formation that commonly lead to graft failure....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $198,936 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to New York University School of Medicine (NYU) for the purpose of studying the impact of restrictive drug coverage policies on heart failure care. The project aims to quantify the effects of cost-sharing requirements and prior authorization policies on provider prescribing practices, patient medication adherence, and clinical outcomes for guideline-recommended...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop novel lipid nanoparticle-based therapies for treating cardiac contractile disorders. The $793,828 award will fund experiments to characterize the efficacy and safety of different inhibitory nucleic acid cargos delivered via cardiotropic lipid nanoparticles (CLNPs) in healthy animal models and human myocardial tissue....